🎉 M&A multiples are live!
Check it out!

Shanghai RAAS Valuation Multiples

Discover revenue and EBITDA valuation multiples for Shanghai RAAS and similar public comparables like Julphar, Armata Pharmaceuticals, and Vivoryon Therapeutics.

Shanghai RAAS Overview

About Shanghai RAAS

Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has a high comprehensive utilization of plasma raw materials and different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The main products are human albumin, intravenous human immunoglobulin, coagulation factor products, etc.


Founded

1988

HQ

China
Employees

272

Website

raas-corp.com

Financials

LTM Revenue $1.2B

LTM EBITDA $359M

EV

$5.8B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Shanghai RAAS Financials

Shanghai RAAS has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $359M.

In the most recent fiscal year, Shanghai RAAS achieved revenue of $1.1B and an EBITDA of $395M.

Shanghai RAAS expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Shanghai RAAS valuation multiples based on analyst estimates

Shanghai RAAS P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $1.2B XXX $1.1B XXX XXX XXX
Gross Profit $475M XXX $463M XXX XXX XXX
Gross Margin 40% XXX 41% XXX XXX XXX
EBITDA $359M XXX $395M XXX XXX XXX
EBITDA Margin 31% XXX 35% XXX XXX XXX
EBIT $329M XXX $306M XXX XXX XXX
EBIT Margin 28% XXX 27% XXX XXX XXX
Net Profit $322M XXX $306M XXX XXX XXX
Net Margin 27% XXX 27% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Shanghai RAAS Stock Performance

As of July 16, 2025, Shanghai RAAS's stock price is CNY 7 (or $1).

Shanghai RAAS has current market cap of CNY 45.5B (or $6.4B), and EV of CNY 41.5B (or $5.8B).

See Shanghai RAAS trading valuation data

Shanghai RAAS Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$5.8B $6.4B XXX XXX XXX XXX $0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Shanghai RAAS Valuation Multiples

As of July 16, 2025, Shanghai RAAS has market cap of $6.4B and EV of $5.8B.

Shanghai RAAS's trades at 5.1x EV/Revenue multiple, and 14.7x EV/EBITDA.

Equity research analysts estimate Shanghai RAAS's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Shanghai RAAS has a P/E ratio of 19.7x.

See valuation multiples for Shanghai RAAS and 12K+ public comps

Shanghai RAAS Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $6.4B XXX $6.4B XXX XXX XXX
EV (current) $5.8B XXX $5.8B XXX XXX XXX
EV/Revenue 4.9x XXX 5.1x XXX XXX XXX
EV/EBITDA 16.2x XXX 14.7x XXX XXX XXX
EV/EBIT 17.6x XXX 19.0x XXX XXX XXX
EV/Gross Profit 12.2x XXX n/a XXX XXX XXX
P/E 19.7x XXX 20.8x XXX XXX XXX
EV/FCF n/a XXX -46.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Shanghai RAAS Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Shanghai RAAS Margins & Growth Rates

Shanghai RAAS's last 12 month revenue growth is 5%

Shanghai RAAS's revenue per employee in the last FY averaged $4.2M, while opex per employee averaged $0.6M for the same period.

Shanghai RAAS's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shanghai RAAS's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Shanghai RAAS and other 12K+ public comps

Shanghai RAAS Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 5% XXX 5% XXX XXX XXX
EBITDA Margin 31% XXX 35% XXX XXX XXX
EBITDA Growth 12% XXX 8% XXX XXX XXX
Rule of 40 35% XXX 39% XXX XXX XXX
Bessemer Rule of X XXX XXX 43% XXX XXX XXX
Revenue per Employee XXX XXX $4.2M XXX XXX XXX
Opex per Employee XXX XXX $0.6M XXX XXX XXX
S&M Expenses to Revenue XXX XXX 4% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 3% XXX XXX XXX
Opex to Revenue XXX XXX 14% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Shanghai RAAS Public Comps

See public comps and valuation multiples for Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Shanghai RAAS M&A and Investment Activity

Shanghai RAAS acquired  XXX companies to date.

Last acquisition by Shanghai RAAS was  XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai RAAS acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Shanghai RAAS

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Shanghai RAAS

When was Shanghai RAAS founded? Shanghai RAAS was founded in 1988.
Where is Shanghai RAAS headquartered? Shanghai RAAS is headquartered in China.
How many employees does Shanghai RAAS have? As of today, Shanghai RAAS has 272 employees.
Is Shanghai RAAS publicy listed? Yes, Shanghai RAAS is a public company listed on SHE.
What is the stock symbol of Shanghai RAAS? Shanghai RAAS trades under 002252 ticker.
When did Shanghai RAAS go public? Shanghai RAAS went public in 2008.
Who are competitors of Shanghai RAAS? Similar companies to Shanghai RAAS include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Shanghai RAAS? Shanghai RAAS's current market cap is $6.4B
What is the current revenue of Shanghai RAAS? Shanghai RAAS's last 12 months revenue is $1.2B.
What is the current revenue growth of Shanghai RAAS? Shanghai RAAS revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Shanghai RAAS? Current revenue multiple of Shanghai RAAS is 4.9x.
Is Shanghai RAAS profitable? Yes, Shanghai RAAS is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Shanghai RAAS? Shanghai RAAS's last 12 months EBITDA is $359M.
What is Shanghai RAAS's EBITDA margin? Shanghai RAAS's last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Shanghai RAAS? Current EBITDA multiple of Shanghai RAAS is 16.2x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.